The United Arab Emirates (UAE) approved Hugel Inc.’s botulinum toxin Botulax.
The approval of Botulax in 50IU, 100IU, and 200IU covers five aesthetic and medical indications: crow’s feet; glabellar lines; eyelid spasm; upper extremity muscle spasticity after stroke; and cerebral palsy adduction deformity in children.
The company plans to officially release the toxin in the Middle East and North Africa (MENA) at the end of April. Medica Group, Hugel’s aesthetic toxin distribution partner headquartered in the UAE with branches in Saudi Arabia and Lebanon, will lead the sales in MENA with its strong regional networks.
